The Wall Street Transcript
The Wall Street Transcript - In-Depth Interviews for Investors
Healthcare >> CEO Interviews >> August 18, 2022

Interview with the Executive Chairman, Interim CEO and Chief Scientific Officer: RespireRx Pharmaceuticals Inc. (OTCMKTS:RSPI)

Lippa, Dr. Arnold
Dr. Arnold Lippa has served as Executive Chairman of RespireRx Pharmaceuticals Inc. since March 2013 and Chief Scientific Officer since August 2015 and is currently Interim CEO. From March 2013 until August 2015 and from September 2018 until May 2020, he also served as President and Chief Executive Officer, respectively. He is a Senior Managing Director and founder of T Morgen Capital LLC through which he administers his family’s assets. T Morgen Capital LLC is a significant equity owner and managing member of Aurora Capital LLC (“Aurora”), a firm of which Jeff Margolis is the president and founder and which has served as a placement agent with respect to certain of the company’s prior financings. Aurora was SEC registered and a FINRA member firm until voluntarily withdrawing effective July 2021 and has been inactive in the securities and investment banking industry since April 2021. Dr. Lippa and Mr. Margolis founded and jointly manage, since 2004, Atypical BioCapital Management LLC and Atypical BioVentures Fund LLC, a life sciences fund management company and venture fund, respectively. Both entities are currently inactive. Dr. Lippa is a member of the Board of Directors of ContraVir Pharmaceuticals, Inc. since December 2015, where he is a member of the audit committee and the compensation committee. Dr. Lippa was co-founder of DOV Pharmaceutical, Inc., where he served as Chairman of the Board and Chief Executive Officer from its inception in 1995 through 2005 and which he took public in 2002. Profile
Word count: 2,466

TWST: So it’s been a few years since you last spoke with the publication. Can you tell us about the history of the company and its mission?

Dr.

Top Company Interviews

Microsoft Corporation
Intel Corporation
Pfizer, Inc.
General Electric Company
Walmart Inc.
International Business Machines Corporation
Citigroup Inc.
Exxon Mobil Corporation
Bank of America Corporation
Dell Inc.
Verizon Communications Inc.
Alphabet Inc
CEO INTERVIEWS
Interview with the CEO: Pasithea Therapeutics Corp. (NASDAQ:KTTA)
Interview with the CEO: BetterLife Pharma Inc. (OTCMKTS:BETRF)
Interview with the CEO: Cansortium Inc. (OTCMKTS:CNTMF)
SECTOR ROUNDTABLES
Natural Gas Weighs Heavy On E&P Near-Term Prospects
Roundtable Forum:optimism Despite Uncertainty In For-profit Education
Roundtable Forum:a Shift In Focus To Natural Gas From Oil
MONEY MANAGER INTERVIEWS
AI Opportunities Expand to Industrial, Utilities and Energy Sectors
India Fund Manager Expects Discretionary Spending to Grow
Inefficiency in Ex-US Markets Creates Opportunity to Buy at a Discount
ANALYST INTERVIEWS
Five Companies Dominate in Psychedelics-Based Drug Development
Cidara’s Long-Acting Antiviral Drug Could Be a Game Changer
Spotting Potential in the High-Risk, High Reward Neuroscience Space
Since 1963
© The Wall Street Transcript 2016, 2024
Terms and Conditions
Privacy Policy